- Home
- CHRS vs BWAY Comparison
CHRS vs BWAY Comparison
Compare CHRS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BWAY
- Stock Information
- Founded
- CHRS 2010
- BWAY 2003
- Country
- CHRS United States
- BWAY Israel
- Employees
- CHRS N/A
- BWAY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BWAY Medical/Dental Instruments
- Sector
- CHRS Health Care
- BWAY Health Care
- Exchange
- CHRS Nasdaq
- BWAY Nasdaq
- Market Cap
- CHRS 84.2M
- BWAY 201.1M
- IPO Year
- CHRS 2014
- BWAY 2019
- Fundamental
- Price
- CHRS $0.73
- BWAY $13.15
- Analyst Decision
- CHRS Buy
- BWAY Strong Buy
- Analyst Count
- CHRS 3
- BWAY 2
- Target Price
- CHRS $4.68
- BWAY $14.25
- AVG Volume (30 Days)
- CHRS 1.3M
- BWAY 52.0K
- Earning Date
- CHRS 08-07-2025
- BWAY 08-05-2025
- Dividend Yield
- CHRS N/A
- BWAY N/A
- EPS Growth
- CHRS N/A
- BWAY N/A
- EPS
- CHRS N/A
- BWAY 0.08
- Revenue
- CHRS $272,251,000.00
- BWAY $43,457,000.00
- Revenue This Year
- CHRS N/A
- BWAY $351.53
- Revenue Next Year
- CHRS $106.56
- BWAY $21.84
- P/E Ratio
- CHRS N/A
- BWAY $65.66
- Revenue Growth
- CHRS 19.87
- BWAY 26.86
- 52 Week Low
- CHRS $0.66
- BWAY $5.67
- 52 Week High
- CHRS $2.43
- BWAY $13.35
- Technical
- Relative Strength Index (RSI)
- CHRS 41.45
- BWAY 75.58
- Support Level
- CHRS $0.72
- BWAY $10.84
- Resistance Level
- CHRS $0.77
- BWAY $11.40
- Average True Range (ATR)
- CHRS 0.04
- BWAY 0.53
- MACD
- CHRS 0.00
- BWAY 0.18
- Stochastic Oscillator
- CHRS 13.65
- BWAY 92.59
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.